Acadian Asset Management LLC purchased a new stake in shares of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 7,577 shares of the technology company’s stock, valued at approximately $174,000. Acadian Asset Management LLC owned approximately 0.37% of Opiant Pharmaceuticals at the end of the most recent reporting period.

In related news, major shareholder Geoffrey Wolf sold 2,570 shares of Opiant Pharmaceuticals stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $30.40, for a total value of $78,128.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 63.82% of the stock is owned by company insiders.

OPNT has been the subject of several analyst reports. TheStreet downgraded Opiant Pharmaceuticals from a “c+” rating to a “d+” rating in a report on Monday, December 11th. ValuEngine downgraded Opiant Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, October 27th.

Opiant Pharmaceuticals Inc (OPNT) opened at $19.90 on Thursday. Opiant Pharmaceuticals Inc has a twelve month low of $5.00 and a twelve month high of $51.90. The firm has a market capitalization of $39.91, a price-to-earnings ratio of 47.38 and a beta of -2.85.

Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its quarterly earnings results on Monday, December 4th. The technology company reported ($2.77) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($1.58). Opiant Pharmaceuticals had a net margin of 8.93% and a return on equity of 42.44%. The company had revenue of $0.02 million for the quarter. equities analysts forecast that Opiant Pharmaceuticals Inc will post 0.17 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Acadian Asset Management LLC Takes $174,000 Position in Opiant Pharmaceuticals Inc (OPNT)” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at

Opiant Pharmaceuticals Profile

Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with's FREE daily email newsletter.